Background {#Sec1}
==========

Dental plaque is the main etiological factor of periodontal diseases, mainly plaque-induced gingivitis \[[@CR1], [@CR2]\]. The latter is the most common inflammatory condition of the gingiva, affecting a large segment of the population \[[@CR1]\]; hence, gingivitis is frequently encountered in the daily dental practice \[[@CR3]\]. Gingivitis is a preventable and reversible condition. However, if left untreated, gingivitis can progress into periodontitis and eventually tooth loss and edentulism \[[@CR3]\]. Thus, dental plaque must be brought under control via proper oral hygiene.

Improper oral hygiene is the main risk factor for periodontal diseases, irrespective of the age \[[@CR1], [@CR2]\]. Therefore, adequate and proper plaque control measures have to be applied regularly \[[@CR2]\]. Nevertheless, mechanical methods might not be feasible and/or sufficient \[[@CR4]\]. Hence, chemical preparations such as antimicrobial mouthwashes have been suggested either as an adjunctive or as a replacement for mechanical plaque control \[[@CR4]\].

Owing to their ease of use and availability over the counter, the public highly appreciate mouthwashes. Chlorhexidine mouthwash (CHX) is considered as the gold standard antiplaque agent \[[@CR4]\]. CHX (a broad spectrum cationic, bisbiguanide antiseptic) is used in diverse medical fields, mainly due to its antibacterial nature \[[@CR4]\]. CHX seems to exert an instant bactericidal effect followed by an extended bacteriostatic effect \[[@CR4]\]. Nevertheless, long term-use of CHX has been linked with numerous adverse effects including altered taste perception, staining of teeth and tongue, burning sensation and genotoxicity of buccal epithelial cells \[[@CR5], [@CR6]\]. Consequently, pharmaceutical companies have long been attempting to formulate natural-derived oral care products \[[@CR7]--[@CR9]\]. Among these, propolis -a natural resinous material produced by honey bee- has recently been proposed as an alternative anti-plaque mouthwash \[[@CR8], [@CR10]\]. The chemical composition of propolis includes 50% resin, 30% wax, 10% aromatic and essential oils, 5% pollen and 5% other constituents \[[@CR10]--[@CR12]\]. The flavonoids are the main biologically dynamic constituents of propolis extracts, suggesting homogeneity of propolis preparations, making their use harmless compared to many other synthetic products \[[@CR13]\]. Propolis has shown strong antimicrobial and anti-inflammatory properties, making it a good candidate for treatment and prevention of oral diseases \[[@CR12], [@CR14]--[@CR16]\]. In this context, a number of clinical trials have investigated the efficacy of propolis on plaque and gingivitis, and conflicting results were reported \[[@CR8], [@CR14], [@CR17], [@CR18]\]. While some studies found equal or even superior efficacy in favor of propolis \[[@CR17]--[@CR22]\], others reported better efficacy with CHX \[[@CR8], [@CR14]\].

Owing to the contradictory reports, the current systematic review aimed to evaluate the available evidence on the efficacy of propolis-based mouthwashes in comparison with CHX on dental plaque and gingival inflammation.

Methods {#Sec2}
=======

Focused question {#Sec3}
----------------

The present systematic review strictly adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and PICO principles \[[@CR23]\]. The protocol of this systematic review was also registered at PROSPERO (ID = CRD42020156187). The focused PICO question was: compared to CHX, what is the efficacy of propolis-based mouthwashes on plaque and gingivitis?

Eligibility criteria {#Sec4}
--------------------

The following eligibility criteria were applied: 1) Study design: Randomized controlled trials (RCT); 2) Participants: Systemically healthy adults aged ≥18 years; 3) Intervention: propolis-based mouthwash of any concentration; 4) Comparison group: CHX mouthwash of any concentration; 5) Outcomes: gingival inflammation and/or plaque index; 6) Follow-up period: any time with no restriction on the follow-up time; and 7) Language: articles published in English.

Literature search {#Sec5}
-----------------

A comprehensive literature search of PubMed/Medline, Scopus, and Web of Science (ISI) databases was conducted in December 2019 for all relevant studies from the date of inception up to and including November 2019. A combination of the following keywords and Medical Subject Heading (MeSH) terms were used: ("propolis" OR "honey" OR "honeybee" OR "bee glue") AND ("gingivitis" OR "gingival health" OR "gingival disease" OR "dental plaque" OR "dental health" OR "periodontitis" OR "periodontal health" OR "periodontal disease"). The titles and abstracts of the retrieved studies were screened independently by two reviewing groups composed of two reviewers each (AS, AM) and (AA, AA), and irrelevant studies were excluded. Disagreements, if any, were resolved by discussion or by a reviewer not involved in the screening. Full-text of the potentially eligible studies were obtained and evaluated independently by the two reviewing groups for inclusion. Respective authors were contacted whenever deemed necessary. Additionally, the references of the retrieved studies were hand-searched for any additional studies. One of the included studies lacked some important data, and hence the respective authors were contacted via email; thankfully, the authors responded and provided all missing information.

Risk of bias assessment (quality assessment) {#Sec6}
--------------------------------------------

Risk of bias of the included studies was carried out independently by two reviewers (AS and AA) according to the Cochrane risk of bias assessment tool \[[@CR24]\]. The following domains were assessed: sequence generating; allocation concealment; blinding of participants and personnel; blinding of outcome assessment; incomplete outcome data; selective outcome reporting; and other sources of bias. Accordingly, the overall risk of bias of each included study was judged as either: low, all criteria were of low risk; unclear, at least one criterion was evaluated to be of unclear risk but no criterion of high risk; or high, at least one criterion with high risk of bias \[[@CR24]\].

Data extraction {#Sec7}
---------------

The following data were extracted and tabulated by two authors (AS and AM): authors and year of the study, the study design, country, number of participants, mean ages, gender, concentration of propolis and CHX, frequency of use per day, follow-up period, side effects, clinical parameters; and main outcomes.

Results {#Sec8}
=======

Study selection {#Sec9}
---------------

A total of 849 articles were retrieved, 248 of which were duplicates and thus were removed. The titles and abstracts of the remaining 601 articles were screened independently by the two-reviewing groups, and 559 were excluded because they did not fulfill the eligibility criteria. The full-text of the remaining 42 articles were obtained and evaluated for inclusion. Of these, 33 articles were excluded for various reasons (list of the excluded studies and the reason of exclusion are presented in supplementary Table [1](#MOESM1){ref-type="media"}). Eventually, 9 studies fulfilled the eligibility criteria and were processed for data extraction.

General characteristics of the included studies {#Sec10}
-----------------------------------------------

General characteristics of the included studies are presented in Table [1](#Tab1){ref-type="table"}. Nine randomized clinical trials (RCT) involving 333 patients were included in this systematic review \[[@CR8], [@CR11], [@CR14], [@CR17]--[@CR22]\] (Table [1](#Tab1){ref-type="table"}). Four studies were conducted in India \[[@CR14], [@CR20]--[@CR22]\], two in Brazil \[[@CR17], [@CR18]\], one in Iran \[[@CR11]\], one in Iraq \[[@CR19]\], and one in the UK \[[@CR8]\]. Number of subjects ranged between 10 and 60 subjects. All included studies enrolled healthy subjects with no history of systemic diseases. Medications or dentifrices known to affect the intervention were considered as exclusion criteria in all included studies. Three studies \[[@CR11], [@CR17], [@CR21]\] reported excluding smokers, while the remaining studies did not provide any information about smoking status of the participants. The evaluation period ranged from 5 to 28 days. Six studies \[[@CR11], [@CR14], [@CR17], [@CR19], [@CR20], [@CR22]\] reported the age of the participants (age range: 15--70 years). Only three studies \[[@CR11], [@CR19], [@CR20]\] reported the gender of the participants; the number of female subjects varied among the studies and ranged from 2 to 27. Two studies \[[@CR8], [@CR21]\] neither mentioned the age nor the gender of the subjects (Table [1](#Tab1){ref-type="table"}). Table 1General characteristics of the included studiesAuthors/Year (country)Type of studyM/F (Age range)Study Groups (Sample size)IndexDiagnosis of gingivitisConcentration / Composition of propolisProfessional procedure/ Hygiene during trialSmoking/ Ortho. applianceFrequency of mouthwashes used/ durations of rinsing per timeFollow-up PeriodStudy outcomeMurray et al. 1997 \[[@CR8]\] (UK)Double blind three group parallel study41G1:propolis(*n* = 13)G2:CHX 0.12%(*n* = 14)PI--Propolis Extract 10% in ethanol, polyoxyethelers, Hydrogenated castor oil, sodium nipasept and waterScaling and polishing, 1 week before.NMTwice a day for 1 min5 daysCHX was significantly more effective than propolis in reducing plaque.Santiago 2018 \[[@CR18]\] (Brazil)Three group parallel study(20--40 years)G1:propolis(n=)G2:CHX(n=)G3:propolis plus CHX(n=)PI (PHP)--Propolis-containing mouthwashDental plaque was removed at the beginning of the stuy, standard toothbrushes, toothpaste and flossNMNM14 daysPropolis and CHX showed comparable results in reducing plaquePorwal et al. 2018 \[[@CR22]\] (India)Three group parallel RandomizedClinical trial(20--40)G1: propolis (*n* = 10)G2: CHX 0.2%(*n* = 10)PI & GINMRaw propolis diluted with distilled water (1:1)Thorough scaling and root planningOrtho. treatment or bridge work were excluded10 ml mouthwash twice daily28 dayPropolis was comparable to CHX in reducing plaque but more effective in reducing gingival inflammation.Krishna et al. 2019 \[[@CR20]\] (India)RandomizedControlled clinical trial27/18 (18--70)G1: propolis(*n* = 15)G2: CHX 0.2%(*n* = 15)PI & GIChronic generalized gingivitis5% propolisScaling and root planningNM10 ml daily Twice at morning & twice at night6 weeksPropolis showed significantly better efficacy than CHX in reducing GI and PI .Dodwad and Kukreja 2011 \[[@CR14]\] (India)A single blind three-group parallel study(18--50)G1: propolis(*n* = 10)G2: CHX 0.2%(*n* = 10)PI & GIChronic generalized gingivitisNMProfessionally scaled and polished, and to refrain from all other oral hygiene measures until the final examinationNMTwice a day for one min.5 daysCHX showed slight better efficacy than propolis in reducing plaque. Propolis was marginally better in reducing gingival inflammation thanSavita et al. 2018 \[[@CR21]\] (India)Randomized Clinical Crossover StudyNMG1: Propolis(*n* = 20)G2: CHX 0.2%(*n* = 20)PI & GIModerate to severe gingivitis20% Propolis Food grade alcohol, Glycerine, Sorbitol, Menthol, Saccharin, Benzyl alcohol and flavor Anise MintSupragingival ultrasonic scaling was carried out in the same appointmentsSmoking, tobacco chewing.10 ml twice daily for two Weeks2 weeksPropolis and CHX were equally effective in reducing PI and GI.Abdullah et al. 2003 \[[@CR19]\] (Iraq)Double-blind crossover design108/2(20--24)G1: propolis (*n* = 10)G2: propolis (ethanol extract)(*n* = 10)G3: CHX 0.2%(*n* = 10)PI--(0.5, 1% water extract of propolis, 0.5, 1% ethanolic extract of propolis) with distilled waterProfessional scaling & polishing, daily tooth brushing & flossing then abstain all mechanical tooth cleaning effort for the next five daysNo any appliance15 ml three times daily for one minute each time5 daysPropolis 1% ethanolic extract was as effective as CHX in reducing plaqueDehghani et al. 2019 \[[@CR11]\] (Iran)Triple-blind parallel-groupClinical trial.10\\27 (15--35)G1:popolis(*n* = 18)G2: CHX 0.12%(*n* = 19)PI &GIMild to moderate gingivitisPropolis aqueous extract, Propolis was 1% with a salt concentration of 0.25%, oil of saffron and flavorSubjects continue their usual daily brushing method (tooth brush and dental floss) during the study periodNon- smokers under fixed ortho. Treatment15 ml, twice a day after brushing, for 1 min3 weeksBoth mouthwashes were equally efficacious in reducing plaque and gingivitisAnauate-Netto et al. 2014 \[[@CR17]\] (Brazil)Randomized double-blind, placebo-controlled clinical trial(18--55 yeas)G1: propolis(*n* = 20)G2: CHX 0.12%(*n* = 20)PBSNo clinical signs of periodontal diseaseAlcohol-free, 2% typified propolis, mintFlavor, water, polioxyethelers, sorbitol and blue colorNoneNot being a current smoker15 ml of mouthrinse twice a day after ordinary oral hygiene procedures28 daysPropolis mouthrinse was superior to CHX in reducing mean PBS (*P* \< 0.05).*GI* Gingival Index, *PI* Plaque Index, *CHX* Chlorhexidine, *NM* Not mentioned, *PHP* Patient Hygiene Performance, *PBS* Papillary Bleeding Score

Intervention and comparison groups {#Sec11}
----------------------------------

All included studies compared propolis-based mouthwashes with CHX \[[@CR8], [@CR11], [@CR14], [@CR17]--[@CR22]\] (Table [1](#Tab1){ref-type="table"}). Eight studies \[[@CR8], [@CR11], [@CR14], [@CR17], [@CR18], [@CR20]--[@CR22]\] used the raw propolis, while one study \[[@CR19]\] used two formulations of propolis namely, water extract poroplis and ethanol extract propolis (Table [1](#Tab1){ref-type="table"}). With regards to the control group, seven studies reported on CHX concentrations: five studies used CHX 0.2% \[[@CR14], [@CR19]--[@CR22]\], and two studies used CHX 0.12% \[[@CR8], [@CR17]\] (Table [1](#Tab1){ref-type="table"}).

Outcome measures {#Sec12}
----------------

Dental plaque was assessed in eight included studies \[[@CR8], [@CR11], [@CR14], [@CR18]--[@CR22]\]. Methods of recording the plaque were highly variable across the included studies: three studies used Silness and Loe plaque index (PI) \[[@CR8], [@CR11], [@CR19]\]; three used Turesky-Gilmore-Glickman modification of Quigley-Hein PI \[[@CR14], [@CR21], [@CR22]\]; and one used the Patient Hygiene Performance \[[@CR18]\]. One study did not mention the type of plaque scoring index \[[@CR20]\]. With regards to gingival inflammation, six studies reported on this outcome \[[@CR11], [@CR14], [@CR17], [@CR20]--[@CR22]\]. Three of these studies \[[@CR11], [@CR14], [@CR21]\] used Loe and Silness gingival index (GI), and one study \[[@CR22]\] used the modified GI by Lobene. Contrastingly, one study used the papillary bleeding index \[[@CR17]\]; whereas one study did not provide any information about the scoring index \[[@CR20]\].

Main outcomes {#Sec13}
-------------

Out of the eight studies \[[@CR8], [@CR11], [@CR14], [@CR18]--[@CR22]\] that reported on PI, 5 studies \[[@CR11], [@CR18], [@CR19], [@CR21], [@CR22]\] found comparable results between the two groups and one study \[[@CR20]\] found propolis-based mouthwashes superior to CHX in reducing plaque. Conversely, two studies reported CHX superior to propolis-based mouthwashes in reducing dental plaque \[[@CR8], [@CR14]\] (Table [1](#Tab1){ref-type="table"} & supplementary Table [2](#MOESM2){ref-type="media"}).

Out of the six studies that reported on gingival inflammation outcome, four studies \[[@CR14], [@CR17], [@CR20], [@CR22]\] reported propolis-based mouthwashes to be superior to CHX in reducing gingival inflammation. Two studies \[[@CR11], [@CR21]\] found comparable results in reducing gingival inflammation (Table [1](#Tab1){ref-type="table"} and supplementary Table [2](#MOESM2){ref-type="media"}).

Side effects {#Sec14}
------------

Eight studies \[[@CR8], [@CR11], [@CR14], [@CR18]--[@CR22]\] reported no side effects of the assessed mouthwashes. One study \[[@CR17]\] reported some adverse effects (e.g., burning, taste alterations, yellow teeth, breath alteration, tongue burning, bitter taste) in 23 participants of CHX group, and in 7 participants of propolis group.

Risk of bias of the included studies {#Sec15}
------------------------------------

The risk of bias assessment results are summarized in Table [2](#Tab2){ref-type="table"}. Only two studies \[[@CR11], [@CR17]\] were at low risk of bias, while the majority of included studies \[[@CR8], [@CR14], [@CR18]--[@CR20], [@CR22]\] were at high risk of bias and one study \[[@CR21]\] showed unclear risk of bias (Table [2](#Tab2){ref-type="table"}). Table 2A summary of the risk of bias assessment of the included studiesStudySequence generationAllocation concealmentBlinding of participantsBlinding of outcomeIncomplete outcome dataSelective outcome reportingOther potential threats to validityEstimated risk of bias within studyAnauate-Netto et al.Low riskLow riskLow riskLow riskLow riskLow riskLow riskLow riskDehghani et al.Low riskLow riskLow riskLow riskLow riskLow riskLow riskLow riskAbdullah et al.Low riskHigh riskLow riskHigh riskLow riskLow riskLow riskHigh riskDodwad and KukrejaLow riskLow riskLow riskHigh riskLow riskLow riskLow riskHigh riskSavita et al.Low riskLow riskUnclear riskUnclear riskUnclear riskLow riskLow riskUnclear riskSantiago et al.High riskHigh riskHigh riskHigh riskUnclear riskLow riskHigh riskHigh riskMurray et al.Low riskLow riskLow riskUnclear riskLow riskLow riskLow riskHigh riskPorwal et al.Low riskLow riskUnclear riskHigh riskLow riskLow riskLow riskHigh riskKrishna et al.Low riskLow riskUnclear riskHigh riskLow riskLow riskLow riskHigh risk

Discussion {#Sec16}
==========

To the best of our knowledge, this is the first systematic review that assessed the available evidence regarding the efficacy of propolis-based mouthwashe in comparison to CHX in reducing plaque accumulation and gingival inflammation. Overall, the findings of the qualitative analysis suggest that propolis-based mouthwashes are comparable to CHX in reducing plaque, but more efficacious in reducing gingival inflammation. Additionally, the results showed that propolis-based mouthwashes are safe with no or minimal reported side effects. Nevertheless, these findings should be interpreted with caution, given some methodological weaknesses discussed in the subsequent sections.

One of the main outcomes assessed in the present review was the efficacy of propolis-based mouthwashea in reducing dental plaque. The results showed positive antiplaque efficacy of propolis comparable to CHX, the gold standard mouthwash for plaque. Propolis has been shown to have antibacterial properties against different strains of aerobic and anerobic oral pathogens, probably due to the flavonoid content of propolis \[[@CR12], [@CR15], [@CR18]\]. Another important finding of the present systematic review is the potent anti-gingivitis effects of propolis-based mouthwashes. Among the included nine studies, six randomized clinical trials \[[@CR11], [@CR14], [@CR17], [@CR20]--[@CR22]\] included gingival inflammation as an outcome; of these, four studies \[[@CR14], [@CR17], [@CR20], [@CR22]\] reported better outcomes with propolis-based mouthwashes, whereas two studies \[[@CR11], [@CR21]\] reported propolis-based mouthwashes as efficacious as CHX in reducing gingival inflammation. The superior efficacy of propolis-based mouthwashes in reducing gingival inflammation can be attributed to the propolis' potent anti-inflammatory properties. Recent in-vivo and in-vitro studies have shown that propolis inhibits prostaglandin production through inhibiting lipoxygenase and cyclooxygenase enzymes, resulting in a rapid and potent reduction in pain and tissue inflammation \[[@CR12], [@CR25]\].

Undoubtedly, CHX is the most widely used mouthwash for plaque and gingivitis \[[@CR5]\]. However, CHX has been linked with numerous side effects including, but not limited to, taste changes, and teeth staining. The present systematic review revealed that propolis-based mouthwashes were safe and well-tolerated, suggesting that the propolis-based mouthwashes can be considered as safe and viable alternatives to CHX.

Definitive conclusions can only be drawn from high quality studies. For this purpose, we critically analyzed the included studies using the Cochrane Collaboration's tool for assessing risk of bias. The results showed that most of the included studies were of low quality as reflected by the high risk of bias in these studies, making it difficult to draw a robust conclusion. Another concerning issue is the obvious methodological discrepancies in reporting and measuring the outcomes across the included studies. This in fact precluded us from pooling the data and performing meta-analysis.

Adequate follow-up period is central for evaluating the clinical efficacy of any mouthwash \[[@CR26]\]. In the present review, the follow-up period was highly variable among the included studies: 5 days in three studies, 14 days in two studies, 21 days in one study, 28 days in 2 studies and 6 weeks days in one study (Table [1](#Tab1){ref-type="table"}). Apart from being inconsistent, the overall follow-up time adopted by all included studies was rather short, considering the 6 month- evaluation period recommended by the American Dental Association (ADA) \[[@CR26]\]. Obviously, this is a remarkable limitation of the present study, which further weakens the obtained evidence.

Certainly, the results of the present systematic review support the clinical efficacy of propolis-based mouthwashes for controlling plaque and gingivitis. However, there are many limitations that should be acknowledged. The main limitation is the small sample sizes along with low quality of some of the included studies. Another important limitation is the substantial heterogeneity among the included studies with respect to outcomes measurements, duration of evaluation, dose and formulations of the propolis-based mouthwashes, and gender and age of the participants. Furthermore, the present systematic review included only studies published in English and searching only three databases for the relevant studies and thus we may have missed some potential studies.

Conclusion {#Sec17}
==========

The present study suggests that propolis-based mouthwashes may have good clinical efficacy in reducing plaque and gingival inflammation. However, due to the marked methodological variability across the included studies as well as the high risk of bias in some of the included studies, further well-designed clinical trials with adequate follow-up period and standardized methodologies are highly recommended to discern the clinical efficacy of propolis-based mouthwashes before advising to use them in clinical practice.
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